ArticleJournal of orthopaedic research : official publication of the Orthopaedic Research Society2026
Repurposing Metformin to Promote Fracture Callus Maturation via AMPK-Driven Metabolic Activation.
Article in Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Femoral shaft fractures cause prolonged disability, and therapies that accelerate bone repair remain limited. Repurposing clinically approved drugs that target biological bottlenecks in healing is a promising strategy. This study investigated whether systemic metformin administration, an anti-diabetic medication with known metabolic regulatory effects, enhances fracture repair in a rat open femoral shaft fracture model. Histological, immunofluorescent, micro-CT, and biomechanical analyses were performed at 6 weeks post-injury comparing metformin-treated and vehicle-treated animals. Metformin markedly accelerated callus maturation, evidenced by earlier hyaline cartilage ossification, increased collagen I deposition and fiber organization, and reduced collagen II and III expression compared with controls. Micro-CT analysis demonstrated increased tissue mineral density, trabecular thickness, and bone volume fraction along with reduced connectivity density, indicating more advanced structural consolidation of the callus. Although biomechanical parameters were not significantly different at intermediate time point, ultimate load and stiffness trended higher in metformin-treated animals, consistent with structural advancement. Mechanistically, metformin increased p-AMPK expression, elevated mitochondrial markers (NDUFB8, TFAM), and reduced extracellular HMGB1 release, suggesting enhanced metabolic capacity and attenuated inflammatory stress during repair. Importantly, metformin's effects were most pronounced during the cartilage-to-bone transition phase, supporting a role for metabolic activation in promoting endochondral ossification. Together, these findings demonstrate that systemic metformin administration promotes earlier structural consolidation of the fracture callus through coordinated metabolic and inflammatory modulation, supporting the potential repurposing of this safe and inexpensive drug as an adjunct strategy to enhance bone repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.